Transforming ALS Diagnosis and Drug Discovery
Breakthrough diagnosis and treatments
—reimagining ALS care with cutting-edge technology.
Scroll
About SONoALS
Mission-Driven Science
SONoALS, Inc. is a pioneering startup to redefine how ALS is diagnosed and treated. Our mission is to bring non-invasive, data-rich monitoring to the frontlines of neurodegenerative disease research. The team unites clinical neuroscience and biomedical engineering to make that mission a reality.
Breakthrough Technology
Wearable Ultrasound × AI-Powered Analysis
Revolutionary ultrasound technology combined with AI-powered analysis for Amyotrophic Lateral Sclerosis (ALS) monitoring and diagnosis.
Precision Tools for ALS Research and Beyond
Transforming healthcare through innovative applications in early diagnosis and drug discovery.
Applications
Early and Non-invasive Diagnosis of ALS
- Fasciculations are one of the biomarkers that appear earlier than needle EMG abnormalities.
Drug Discovery Support
Fasciculation biomarkers responding in days
- Pre-clinical drug screening in humans
- Selection of responder groups
- Significant reduction in clinical trial duration
- Personalized medicine
We aim to realize these goals.
News & Press
Latest updates and achievements from SONoALS
Wearable Ultrasound Device Prototype Completed
Connectable to a laptop for simultaneous 4-muscle patch measurement, capable of recording high-quality ultrasound video for 20 minutes
Presented at the Industry-Government-Academia Innovation School hosted by the Japanese Society of Neurology
CEO Saeki presented at the Seeds Development Presentation to an audience of 350
Lecture at Computational Neurology Club (CNC)
CEO Saeki delivered a 90-minute lecture at the 22nd Computational Neurology Club (CNC)
Get in Touch
Ready to learn more about our revolutionary ALS technology? Let's connect.
Company Information
Address
WALLSQUARE Kitanozaka
2-13-15 Yamamoto Ave., Chuo Ward
Kobe City, Hyogo 650-0003, Japan
Established
May 2025
Tadashi Kojima
COO, SONoALS